|
Consensus or Controversy – Gastrointestinal Cancers
Clinical investigators provide concise comments on the management of pancreatic cancer, including selection of therapy for patients in the adjuvant and metastatic treatment settings and the use of erlotinib in their personal treatment algorithms for the disease. Featuring perspectives from Drs Peter C Enzinger, Richard M Goldberg, Axel Grothey, Howard S Hochster, David H Ilson, John L Marshall, David P Ryan, Leonard B Saltz, Eric Van Cutsem and Alan P Venook. Clinical investigators provide concise comments on the management of metastatic colon cancer, including resection of synchronous primary tumors and the use of biologic therapy beyond disease progression. Featuring perspectives from Drs Peter C Enzinger, Richard M Goldberg, Axel Grothey, Howard S Hochster, David H Ilson, John L Marshall, David P Ryan, Leonard B Saltz, Eric Van Cutsem and Alan P Venook. Clinical investigators provide concise comments on the management of Stage II/III colon and rectal cancers and their neoadjuvant and adjuvant therapy selections for younger and healthy older patients. Featuring perspectives from Drs Peter C Enzinger, Richard M Goldberg, Axel Grothey, Howard S Hochster, David H Ilson, John L Marshall, David P Ryan, Leonard B Saltz, Eric Van Cutsem and Alan P Venook. Clinical investigators provide concise comments on choice of therapy after R0 resection of T1N1 gastric cancer (GC) with positive nodes, role of HER2 testing in early and metastatic GC, choice of chemotherapy to combine with trastuzumab for HER2-positive GC, duration of trastuzumab therapy and the role of anti-angiogenic agents in the treatment of metastatic GC. Featuring perspectives from Drs Peter C Enzinger, Richard M Goldberg, Axel Grothey, Howard S Hochster, David H Ilson, John L Marshall, David P Ryan, Eric Van Cutsem and Alan P Venook. Clinical investigators provide concise comments on neoadjuvant systemic therapy and local therapy for unresectable hepatocellular carcinoma (HCC), adjuvant sorafenib and other systemic therapies in patients with resected HCC or HCC with higher-risk features and the management of sorafenib-associated skin toxicity with local treatments. Featuring perspectives from Drs Peter C Enzinger, Axel Grothey, Howard S Hochster, David H Ilson, John L Marshall, David P Ryan, Leonard B Saltz, Eric Van Cutsem and Alan P Venook. Clinical investigators provide concise comments on perioperative or postoperative systemic therapy for resectable isolated hepatic metastases and the optimal neoadjuvant conversion regimen to facilitate removal of borderline resectable hepatic metastases. Featuring perspectives from Drs Peter C Enzinger, Richard M Goldberg, Axel Grothey, Howard S Hochster, David H Ilson, John L Marshall, David P Ryan, Leonard B Saltz, Eric Van Cutsem and Alan P Venook. Clinical investigators provide concise comments on the use of neoadjuvant imatinib, duration of adjuvant imatinib in high-risk, KIT-positive GIST, treatment of pancreatic neuroendocrine tumors (NET) with liver metastasis and usual sequence of therapy for GI NET. Featuring perspectives from Drs Peter C Enzinger, Richard M Goldberg, Axel Grothey, Howard S Hochster, David H Ilson, John L Marshall, David P Ryan, Leonard B Saltz, Eric Van Cutsem and Alan P Venook.
|
